"paper"

It has been already reported that COVID-19 infection may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic… Continue Reading

In this report, the authors examined five patients who had Guillain–Barré syndrome after the onset of coronavirus disease 2019 (Covid-19) infection. Four of the patients had a positive nasopharyngeal swab for SARS-CoV-2 at the onset of the neurologic syndrome, while… Continue Reading

COVID-19 AND NEUROLOGY In this useful consensus paper, the current clinical guidelines and research progress on the management of COVID-19 are summarized, emphasizing on its neurological manifestations.  The aim of consensus was to help neurologists to understand the occurrence, development… Continue Reading

In a case series of 214 patients with coronavirus disease 2019 (COVID-19) Mao et al., report that neurologic symptoms were seen in 36.4% of patients and were more common in patients with severe infection (45.5%) according to their respiratory status.… Continue Reading

This paper addresses the possible proposed neurotropic mechanisms of COVID-19 virus and its analogies and differences with SARS-CoV virus. Indeed, similar to SARS-CoV, COVID-19 virus exploits the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the cells. In particular,… Continue Reading

During the Covid-19 pandemic, most European countries have imposed personal restrictions on their populations in order to inhibit viral transmission and spread of infection. The hardest restriction concerns the imposition not to leave home unless to go to the supermarket,… Continue Reading

Aiming to improve the conditions of people living with neurological disorders, the European Federation of Neurological Associations (EFNA) will focus on three advocacy themes for 2020-2025: Access to treatment, services and support Stigma, isolation and discrimination and Patient empowerment, engagement… Continue Reading

As part of the EU’s Civil Protection Mechanism, on 19 March, the European Commission decided to create a Strategic RescEU Stockpile of medical equipment such as ventilators and protective masks to help EU countries in the context of the COVID-19… Continue Reading

Dr. Tom Jenkins, Chair of the EAN e-Communication Committee interviews Prof. Didier Leys, Editor in Chief of the European Journal of Neurology

Meeting of WHO with EFNA, EAN and EBC to discuss brain health Report Objectives: Platform for all participants to present their ongoing work and discuss potential collaboration in the area of brain health Participants: European Academy of Neurology (EAN): Raad… Continue Reading

I would like to express my deepest gratitude to the European Academy of Neurology for having granted my research training Fellowship at the Neurodegeneration Imaging Group (NIG; www.nig-politis.com), based at the Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology & Neuroscience at King’s College London, UK. The NIG is headed by Professor Marios Politis, who is leading expert in the field of neuroimaging in neurodegenerative diseases.

Global Health – EFNA activities update At EFNA we remain engaged with global health initiatives and actors (you can read about initial reasons for this here: Health is a shared global value). The last couple of months have been rather… Continue Reading

Between the 25th and 28th of September 2019, the German Neurological Society (deutsche Gesellschaft für Neurologie – DGN) held its annual congress at the International Congresscenter in Stuttgart, Germany. As one of the largest neurological gatherings in Europe it was attended by approximately 5,500 health professionals associated with Neurology.

The 11th Regional Teaching Course (RTC) in sub-Saharan Africa (SSA) took place in Accra, Ghana. Dr. A. Charway Felli, President-elect of AFAN hosted the RTC held at the Ghana College of Physicians and Surgeons.

Levetiracetam and NOACs